© 2001 American Heart Association, Inc.
Review |
Gene Transfer as an Approach to Treating Hemophilia
From the University of Pennsylvania School of Medicine and Hematology Division, The Children’s Hospital of Philadelphia, Philadelphia, Pa.
Correspondence to Katherine A. High, MD, The Children’s Hospital of Philadelphia, 3516 Civic Center Blvd, 310 Abramson Research Center, Philadelphia, PA 19104.
Abstract—Hemophilia is an X-linked bleeding diathesis caused by a deficiency of either factor VIII or factor IX. Present treatment for hemophilia involves intravenous infusion of either recombinant or plasma-derived clotting factor concentrates. Problems with this treatment method, including the expense, need for intravenous access, and risks of blood-borne disease transmission, have fueled an interest in developing a gene-transfer approach to treatment. On the basis of experience with protein concentrate therapy, it seems likely that even modest elevations in circulating levels of factor VIII or factor IX can prevent most of the mortality and much of the morbidity associated with the disease. Hemophilia has a number of advantages as a model system for working out strategies for gene transfer as an approach to the treatment of genetic diseases; these include wide latitude in choice of target tissue, a wide therapeutic window for levels of circulating factor, ease of determining therapeutic endpoints, and existence of excellent animal models of the disease. Preclinical studies over the last decade have recently culminated in the initiation of clinical trials of gene transfer for hemophilia A and B. Three trials, each using different vectors and target tissues, are presently underway, and two additional trials are in late planning stages. This report reviews the preclinical data underlying these strategies and the design of the ongoing and proposed clinical trials.
Key Words: hemophilia A • hemophilia B • gene therapy • factor VIII • factor IX
This article has been cited by other articles:
 |
|
 |
|
  M. A. Suckow, A. Zollman, I. Cornelissen, M. Casad, J. Roahrig, F. J. Castellino, and E. D. Rosen Tissue Distribution of Fetal Liver Cells Following In Utero Transplantation in Mice Exp Biol Med, December 1, 2005; 230(11): 860 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Hu, X Zhang, X Dong, L Collins, G J Sawyer, and J W Fabre A remarkable permeability of canalicular tight junctions might facilitate retrograde, non-viral gene delivery to the liver via the bile duct Gut, October 1, 2005; 54(10): 1473 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schuettrumpf, R. W. Herzog, A. Schlachterman, A. Kaufhold, D. W. Stafford, and V. R. Arruda Factor IX variants improve gene therapy efficacy for hemophilia B Blood, March 15, 2005; 105(6): 2316 - 2323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Sabatino, E. Armstrong, S. Edmonson, Y.-L. Liu, M. Pleimes, J. Schuettrumpf, J. Fitzgerald, R. W. Herzog, V. R. Arruda, and K. A. High Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene Blood, November 1, 2004; 104(9): 2767 - 2774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Schnepp, K. R. Clark, D. L. Klemanski, C. A. Pacak, and P. R. Johnson Genetic Fate of Recombinant Adeno-Associated Virus Vector Genomes in Muscle J. Virol., March 15, 2003; 77(6): 3495 - 3504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Mount, R. W. Herzog, D. M. Tillson, S. A. Goodman, N. Robinson, M. L. McCleland, D. Bellinger, T. C. Nichols, V. R. Arruda, C. D. Lothrop Jr, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy Blood, April 15, 2002; 99(8): 2670 - 2676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-I Ma, P. Guo, J. Li, S.-Z. Lin, Y.-H. Chiang, X. Xiao, and S.-Y. Cheng Suppression of Intracranial Human Glioma Growth after Intramuscular Administration of an Adeno-associated Viral Vector Expressing Angiostatin Cancer Res., February 1, 2002; 62(3): 756 - 763. [Abstract] [Full Text] [PDF]
|
|